The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.
Yu-Feng
YF
Li
Xiaolin
X
Liu
Ding-Shen
DS
Liu
Ban-He
BH
Din
Jian-Bin
JB
Zhu
D000293:Adolescent; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D006248:Harringtonines / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D055815:Young Adult
D000972:Antineoplastic Agents, Phytogenic; D001549:Benzamides; D006248:Harringtonines; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000077863:Homoharringtonine; D000068877:Imatinib Mesylate